Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer

被引：0
|
作者：
Horita, Y. [1 ]
Mihara, Y. [1 ]
Hamaguchi, T. [1 ]
机构：
[1] Saitama Med Univ, Int Med Ctr, Gastroenterol Oncol Dept, Hidaka, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
177P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (17) : 3718 - 3729
  • [2] Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
    Sung Yong Han
    Dong Uk Kim
    Young Mi Seol
    Suk Kim
    Nam Kyung Lee
    Seung Baek Hong
    Hyung-Il Seo
    World Journal of Clinical Cases, 2020, (17) : 3718 - 3729
  • [3] Comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as 2nd-line treatment for gastric cancer
    Tsuji, Kunihiro
    Miyajima, Saori
    Kito, Yosuke
    Doyama, Hisashi
    ANNALS OF ONCOLOGY, 2021, 32 : S330 - S330
  • [4] Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
    Guo Xi
    Xu Yaolin
    Ji Yuan
    Fan Yue
    Wang Dansong
    Jin Dayong
    Zhuang Rongyuan
    Wu Lili
    Lou Wenhui
    Zhou Yuhong
    Department of Medical Oncology
    Department of General Surgery
    Department of Pathology
    Department of Traditional Chinese Medicine
    Department of Radiotherapy
    胰腺病学杂志（英文）, 2020, 03 (01) : 35 - 41
  • [5] nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life
    Cidon, E. Una
    Alonso, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S109 - S109
  • [6] Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Filipazzi, V.
    Dalu, D.
    Isabella, L.
    Tosca, N.
    Ferrario, S.
    Gambaro, A.
    Somma, L.
    Fasola, C.
    Pellegrini, I.
    Bombonati, G.
    Curcio, R.
    Damiani, E.
    Cattaneo, M. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer
    Miano, S. T.
    Rossi, G.
    Marsili, S.
    Petrioli, R.
    Pascucci, A.
    Francini, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 22 - 23
  • [8] Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
    Liu, Yuan
    Fang, Shan-shan
    Zhao, Run-sheng
    Liu, Bo
    Jin, Yi-qiang
    Li, Quan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (06)
  • [9] Examination of utility in patients of unresectable or recurrent gastric cancer treated with paclitaxel or nab-paclitaxel or paclitaxel plus ramucirumab in our hospital
    Kii, T.
    Gotoh, M.
    Terazawa, T.
    Yamaguchi, T.
    Asaishi, K.
    Aoki, M.
    Ikegami, T.
    Higuchi, K.
    ANNALS OF ONCOLOGY, 2017, 28 : 61 - 61
  • [10] Gemcitabine plus nab-paclitaxel in Japan
    Ioka, Tatsuya
    Katayama, Kazuhiro
    Ookawa, Kazuyoshi
    Takahashi, Hidenori
    Teshima, Teruki
    ANNALS OF ONCOLOGY, 2016, 27
12345